NICOLE DE ANGELIS: Open Payments
NPI 1043805401 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,757 in 124 payments from 13 companies in 2025. Trend: 2023 $1,839 · 2024 $1,300 · 2025 $3,757
Food & beverage: $2,622Travel & lodging: $1,136
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $1,613 |
| GlaxoSmithKline, LLC. | 52 | $636 |
| AstraZeneca Pharmaceuticals LP | 12 | $438 |
| Regeneron Healthcare Solutions, Inc. | 11 | $339 |
| Insmed, Inc. | 15 | $250 |
| Verona Pharma, Inc. | 9 | $220 |
| Baxter Healthcare | 3 | $76 |
| Amgen Inc. | 2 | $50 |
| GENZYME CORPORATION | 2 | $47 |
| United Therapeutics Corporation | 1 | $29 |
Products named: NUCALA, DUPIXENT, AIRSUPRA, Arikayce, TRELEGY ELLIPTA, Ohtuvayre, FASENRA, OFEV.
Industry payments across CA — which companies pay providers there.
